
A post hoc analysis of the REALITI-A study demonstrated that mepolizumab reduced asthma exacerbations in patients with severe asthma and both allergic and eosinophilic phenotypes. The reduction in clinically significant exacerbations was observed across all IgE levels, atopic status, and eosinophil count thresholds, supporting mepolizumab's real-world effectiveness in this patient population.
Like
Save
Share